Table 2.
Frequency of antecedent infections in patients with Guillain‐Barré syndrome and the controls.
| GBS (n = 150) | OND controls (n = 150) | OR (95% CI) | P value |
HC (n = 150) |
OR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|
| No infection | 70 (47) | 128 (85) | Reference | 132 (88) | Reference | ||
| Campylobacter jejuni | 40 (27) | 10 (7) | 7.3 (3.5, 15.5) | <0.001 | 13 (9) | 5.8 (2.9, 11. 6) | <0.001 |
| Influenza A | 26 (17) | 8 (5) | 5.9 (2.6, 13.8) | <0.001 | 10 (7) | 4.9 (2.2, 10.7) | <0.001 |
| Influenza B | 24 (16) | 7 (5) | 6.3 (2.6, 15.3) | <0.001 | 9 (6) | 5.0 (2.2, 11.4) | <0.001 |
| Hepatitis A virus | 7 (5) | 3 (2) | 4.3 (1.1, 17.0) | 0.027 | 0 (0) | ‐ | ‐ |
| Dengue virus | 4 (3) | ||||||
| Cytomegalovirus | 4 (3) | ||||||
| Epstein–Barr virus | 4 (3) | ||||||
| Mycoplasma pneumoniae | 3 (2) | ||||||
| Herpes simplex virus | 3 (2) | ||||||
| Varicella‐zoster virus | 2 (1) | ||||||
| Rubella virus | 1 (1) |
The data are shown as n (%).
OR, odds ratio; CI, confidence interval; GBS, Guillain‐Barré syndrome; OND, other neurological disease; HC, healthy controls. No infection of the hepatitis E virus, Haemophilus influenzae, and Zika virus was detected.